Hoth Therapeutics Inc Stock Price, News & Analysis

Hoth Therapeutics (NASDAQ: HOTH) announced the pricing of an underwritten public offering of 8,235,294 shares of common stock at $0.85 per share, aiming for gross proceeds of approximately $7.0 million. The offering will close on or about April 14, 2022, subject to customary conditions. The funds will be used for general corporate and working capital purposes. EF Hutton is acting as the sole book-running manager. The offering falls under a 'shelf' registration statement declared effective on March 11, 2020.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced an underwritten public offering of common stock, managed by EF Hutton. The offering is made under a 'shelf' registration statement effective since March 11, 2020. It aims to gather funds to support Hoth's development of innovative therapies targeting unmet medical needs in various health areas, including skin toxicities and Alzheimer’s Disease. A prospectus supplement will provide additional details and will be filed with the SEC.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced significant progress on its cancer therapeutic, HT-KIT. This innovative treatment showed effectiveness in preventing cancer cell growth and inducing cell death in mast cell leukemia models. HT-KIT has been granted Orphan Drug status and successfully completed API manufacturing feasibility. The therapy targets the proto-oncogene KIT, aimed at treating rare cancers such as systemic mastocytosis and acute myeloid leukemia. Hoth is preparing for a Pre-IND meeting with the FDA and pursuing various patent applications to safeguard its intellectual property.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced that Dr. Stefanie Johns, Chief Scientific Officer, will present updates on the company's pipeline, including proof-of-concept data for HT-ALZ, a novel Alzheimer's Disease therapeutic. The presentation is scheduled for the BIO International Convention in San Diego, California, from June 13-16, 2022. Hoth Therapeutics focuses on developing therapies for unmet medical needs, specifically targeting issues related to Alzheimer's, skin toxicities from cancer treatment, and other conditions. For more details, visit their website.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced significant development milestones for its cancer therapeutic, HT-KIT, following its receipt of Orphan Drug Designation from the FDA on March 11, 2022. HT-KIT targets the proto-oncogene cKIT and has shown promise in preclinical studies by inducing apoptosis in neoplastic mast cells. The company has completed manufacturing feasibility of HT-KIT in collaboration with WuXi STA and aims to hold a Pre-IND meeting with the FDA by the end of 2022, indicating progress towards advancing its clinical development.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has announced that the FDA has granted Orphan Drug designation to its new molecular entity, HT-KIT, for treating mastocytosis. This antisense oligonucleotide targets the cKIT proto-oncogene, showing promise in preclinical studies by inducing apoptosis in neoplastic mast cells. The Orphan Drug designation aids in development by providing tax credits, fee exemptions, and seven years of market exclusivity post-approval. HT-KIT aims to address rare but serious conditions like aggressive systemic mastocytosis, and its development is led by Hoth's scientific team.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) has partnered with NUVISAN, a European CRO/CDMO, to manufacture clinical batches of its HT-001 topical drug for the upcoming CLEER-001 trial targeting skin toxicities in cancer therapy. This phase 2a randomized, placebo-controlled study will evaluate the efficacy, safety, and tolerability of HT-001 for patients undergoing EGFR inhibitor treatments at 14 sites in the United States. The collaboration aims to leverage NUVISAN's expertise in topical formulation to enhance the clinical development of this therapy.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) announced its submission of preclinical data on HT-ALZ for presentation at the Alzheimer's Association International Conference from July 31 - August 4, 2022, in San Diego. Dr. Carla Yuede, the lead researcher, will present findings from a sponsored research agreement with Washington University. This data is crucial in evaluating HT-ALZ's potential in treating Alzheimer's disease and aligns with Hoth's mission to address unmet medical needs across various indications, including neurological disorders.

Hoth Therapeutics, Inc. (NASDAQ: HOTH) appointed Dr. John Cirrito and Dr. Carla Yuede to its Scientific Advisory Board to lead the development of HT-ALZ, an oral therapy targeting Alzheimer's disease. Dr. Cirrito, with extensive experience in Alzheimer's research, and Dr. Yuede, a behavioral neuroscience expert, will enhance the company's efforts in this critical area. CEO Robb Knie expressed optimism about their expertise driving the project forward. Hoth also has a sponsored research agreement with Washington University to further the preclinical studies for HT-ALZ.